Moderna has highlighted the publication of antibody persistence data out to six months following the second dose of the Moderna Covid-19 Vaccine. The study evaluated 33 healthy adults in a National Institutes of Health (NIH)-led Phase I trial of Moderna’s vaccine six months after the second dose of 100µg on day 209, and found that antibodies elicited by the vaccine persisted through six months after the second dose. Studies looking into immune responses beyond six months are ongoing.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has initiated a Phase II clinical trial called the Systemic Allergic Reactions to SARS-CoV-2 Vaccination to identify severe allergic reactions to the Moderna and Pfizer/BioNTech Covid-19 vaccines. The researchers will also investigate the biological mechanism behind the reactions and whether a genetic pattern or other factors can determine who is most at risk.
Akili Interactive is collaborating with Weill Cornell Medicine, New York-Presbyterian Hospital and the Vanderbilt University Medical Centre to investigate its digital therapeutic, AKL-T01, for treating patients suffering with cognitive dysfunction after Covid-19, also described as ‘Covid brain fog’. There are currently no existing treatments for cognitive impairments in Covid-19 survivors.